Get started
Author

Sangeeta A. Paisey

Observed names: S. Paisey, Sangeeta A Paisey, Sangeeta Paisey
Observed institutions: National Health Service, Cancer Research UK, Southampton General Hospital, Hampshire Hospitals NHS Foundation Trust, Kings Health Partners, University of Southampton
ORCID: 0000-0002-4304-1940
Observed ORCID: 0000-0002-4304-1940
OpenAlex ID: A5036559199
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol
2021 · Gerhardt Attard, Laura Murphy, et al. · The Lancet · 429
PDF
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial
2022 · Chris C. Parker, Nicholas D. James, et al. · PLoS Medicine · 138
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol
2023 · Gerhardt Attard, Laura Murphy, et al. · The Lancet Oncology · 134
PDF
Goblet Cell Adenocarcinoma of the Appendix: A Systematic Review and Incidence and Survival of 1,225 Cases From an English Cancer Registry
2022 · Kieran Palmer, Scott Weerasuriya, et al. · Frontiers in Oncology · 60
PDF
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial
2024 · Chris C Parker, Noel W Clarke, et al. · The Lancet · 58
On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trials
2026 · Mahaz Kayani, Laura Murphy, et al. · The Lancet Oncology · 11
PDF
Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer: the STAMPEDE Phase 3 Randomized Clinical Trial
2025 · Gianmarco Leone, Francesco Orlando, et al. · JAMA Oncology · 9
Primary renal neuroendocrine neoplasms: A systematic literature review, report of four local cases, and original survival analysis of 63 patients from a national registry 2012–2018
2022 · Sangeeta A. Paisey, Scott Weerasuriya, et al. · Journal of Neuroendocrinology · 8
Patients’ Preferences for Cytoreductive Treatments in Newly Diagnosed Metastatic Prostate Cancer: The IP5-MATTER Study
2024 · Martin J. Connor, Mesfin Genie, et al. · European Urology Oncology · 5
Epidemiology and overall survival of de novo and transformed neuroendocrine prostate cancer: a two-nation population-based study of 1,465 patients from the United States and England
2026 · Sunyoung Choi, Mohamed Mortagy, et al. · Endocrine Related Cancer · 1
Neoadjuvant chemoradiotherapy for pancreatic cancer
2024 · Sangeeta A. Paisey, Andrew R. Bateman · CRC Press eBooks · 1
De-novo versus transformed prostate neuroendocrine carcinoma: a population-based study of 1,326 patients
2025 · Sunyoung Choi, Mohamed Mortagy, et al. · Endocrine Abstracts
Chemotherapy use and its effect on overall survival in gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN): a population based study of 63,911 patients
2025 · Sian Dugmore, Mohamed Mortagy, et al. · Endocrine Abstracts
Systemic anti-cancer therapy in gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC): insights from national cancer registration and analysis service (NCRAS)
2024 · Mohamed Mortagy, El Asmar Marie Line, et al. · Endocrine Abstracts
PO-1568: The Impact of Varying Number of OSEM Subsets on PET Radiomic Features: A Preclinical Study
2020 · E. Alsyed, R. Smith, et al. · Radiotherapy and Oncology
Quantitative clinical imaging of Zr-89: developing the patient pathway
2019 · Andrew Fenwick, Lee Bartley, et al.
Is There a Role for Consolidation Radiotherapy in Hodgkin’s Lymphoma in the Era of the Pet Scan?
2013 · Sangeeta A Paisey, Andrew T Bates, et al. · International Journal of Hematologic Oncology
The role of chemoradiotherapy in sub-optimally resectable locally advanced adenocarcinoma of the pancreas
2008 · R. Gillmore, V. Laurence, et al. · Journal of Clinical Oncology
P3-193: Toxicity and outcome of three dimensional conformal radiotherapy for non small cell lung cancer
2007 · Sangeeta A. Paisey, Martin Rolles, et al. · Journal of Thoracic Oncology
PDF
Works count: 21
Citation count: 999
H-index: 9
I10-index: 8
Year
Topic
Type